Julen Oyarzabal

List of Publications by Year in Descending Order

103 papers	3,679 citations	33 h-index	57 g-index
115 ext. papers	4,290 ext. citations	7.5 avg, IF	5.05 L-index

#	Paper	IF	Citations
103	Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis. *Gut*, **2021**, 70, 388-400	19.2	21
102	Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma. *Hepatology*, **2021**, 73, 2380-2396	11.2	3
101	Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with Efficacy in Multiple Myeloma. *Journal of Medicinal Chemistry*, **2021**, 64, 3392-3426	8.3	5
100	Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors. *European Journal of Medicinal Chemistry*, **2021**, 211, 113109	6.8	2
99	Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death. *Cancer Discovery*, **2021**, 11, 1268-1285	24.4	10
98	Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease. *Nature Communications*, **2021**, 12, 421	17.4	11
97	Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. *Cancers*, **2020**, 12,	6.6	1
96	Towards the understanding of the activity of G9a inhibitors: an activity landscape and molecular modeling approach. *Journal of Computer-Aided Molecular Design*, **2020**, 34, 659-669	4.2	11
95	2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: Evaluation in a Murine Model of Acute Pancreatitis. *Journal of Medicinal Chemistry*, **2020**, 63, 9237-9257	8.3	7
94	A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity. *Cancer Letters*, **2020**, 468, 1-13	9.9	12
93	Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles. *ACS Chemical Neuroscience*, **2019**, 10, 4076-4101	5.7	18
92	Targeting CB and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson's Disease. *Molecular Neurobiology*, **2019**, 56, 5900-5910	6.2	15
91	Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors. *European Journal of Medicinal Chemistry*, **2019**, 168, 87-109	6.8	12
90	Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. *Hepatology*, **2019**, 69, 587-603	11.2	56
89	Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer's Disease. *Frontiers in Aging Neuroscience*, **2019**, 11, 149	5.3	21
88	Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. *Nature Medicine*, **2019**, 25, 1073-1081	50.5	71
87	Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors. *ACS Chemical Neuroscience*, **2019**, 10, 1765-1782	5.7	18

86	Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples. *Neurotherapeutics*, **2018**, 15, 742-750	6.4	5
85	Phenotypic Screening To Discover Novel Chemical Series as Efficient Antihemorrhagic Agents. *ACS Medicinal Chemistry Letters*, **2018**, 9, 428-433	4.3	2
84	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2018**, 150, 506-524	6.8	35
83	Development and Validation of Molecular Overlays Derived from Three-Dimensional Hydrophobic Similarity with PharmScreen. *Journal of Chemical Information and Modeling*, **2018**, 58, 1596-1609	6.1	7
82	Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. *Journal of Medicinal Chemistry*, **2018**, 61, 6546-6573	8.3	16
81	Novel Soluble Epoxide Hydrolase Inhibitors Featuring a 2-Oxaadamantane Moiety: Synthesis, in vitro Profiling and in vivo Evaluation in Murine Models of Acute Pancreatitis. *FASEB Journal*, **2018**, 32, 560.6	0.9	
80	Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms. *Haematologica*, **2018**, 103, 1065-1072	6.6	6
79	Therapeutics discovery: From bench to first in-human trials. *Biomedical Reports*, **2018**, 8, 275-282	1.8	
78	Zebrafish: Speeding Up the Cancer Drug Discovery Process. *Cancer Research*, **2018**, 78, 6048-6058	10.1	80
77	Repurposing ciclopirox as a pharmacological chaperone in a model of congenital erythropoietic porphyria. *Science Translational Medicine*, **2018**, 10,	17.5	31
76	Novel pharmacological maps of protein lysine methyltransferases: key for target deorphanization. *Journal of Cheminformatics*, **2018**, 10, 32	8.6	4
75	Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy. *Journal of Medicinal Chemistry*, **2018**, 61, 6518-6545	8.3	27
74	Information Retrieval and Text Mining Technologies for Chemistry. *Chemical Reviews*, **2017**, 117, 7673-7761	66.1	124
73	CM352 Reduces Brain Damage and Improves Functional Recovery in a Rat Model of Intracerebral Hemorrhage. *Journal of the American Heart Association*, **2017**, 6,	6	14
72	LimTox: a web tool for applied text mining of adverse event and toxicity associations of compounds, drugs and genes. *Nucleic Acids Research*, **2017**, 45, W484-W489	20.1	24
71	Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. *Nature Communications*, **2017**, 8, 15424	17.4	74
70	Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer's Disease. *ACS Chemical Neuroscience*, **2017**, 8, 638-661	5.7	26
69	GPR55: A therapeutic target for Parkinson's disease?. *Neuropharmacology*, **2017**, 125, 319-332	5.5	45

68	Dual epigenetic modifiers for cancer therapy. *Molecular and Cellular Oncology*, **2017**, 4, e1342748	1.2	2
67	A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice. *Neuropsychopharmacology*, **2017**, 42, 524-539	8.7	65
66	Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB Receptors. *Frontiers in Pharmacology*, **2017**, 8, 744	5.6	93
65	Inducing heat shock protein 70 expression provides a robust antithrombotic effect with minimal bleeding risk. *Thrombosis and Haemostasis*, **2017**, 117, 1722-1729	7	6
64	Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA). *PLoS ONE*, **2017**, 12, e0185169	3.7	19
63	Reversible dual inhibitor against G9a and DNMT1 improves human iPSC derivation enhancing MET and facilitating transcription factor engagement to the genome. *PLoS ONE*, **2017**, 12, e0190275	3.7	8
62	Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor. *Oncotarget*, **2017**, 8, 71709-71724	3.3	16
61	In Silico Aptamer Docking Studies: From a Retrospective Validation to a Prospective Case Study-TIM3 Aptamers Binding. *Molecular Therapy - Nucleic Acids*, **2016**, 5, e376	10.7	28
60	The Markyt visualisation, prediction and benchmark platform for chemical and gene entity recognition at BioCreative/CHEMDNER challenge. *Database: the Journal of Biological Databases and Curation*, **2016**, 2016,	5	8
59	Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease. *Brain, Behavior, and Immunity*, **2016**, 57, 94-105	16.6	38
58	Hsp70 protects from stroke in atrial fibrillation patients by preventing thrombosis without increased bleeding risk. *Cardiovascular Research*, **2016**, 110, 309-18	9.9	17
57	Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels. *Journal of Neurochemistry*, **2016**, 136, 403-15	6	31
56	Two Affinity Sites of the Cannabinoid Subtype 2 Receptor Identified by a Novel Homogeneous Binding Assay. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 358, 580-7	4.7	17
55	Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease. *Journal of Medicinal Chemistry*, **2016**, 59, 8967-9004	8.3	59
54	Novel Scaffold FingerPrint (SFP): applications in scaffold hopping and scaffold-based selection of diverse compounds. *Journal of Chemical Information and Modeling*, **2015**, 55, 1-18	6.1	21
53	Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation. *Journal of Immunology*, **2015**, 195, 3180-9	5.3	34
52	CHEMDNER: The drugs and chemical names extraction challenge. *Journal of Cheminformatics*, **2015**, 7, S1	8.6	120
51	The CHEMDNER corpus of chemicals and drugs and its annotation principles. *Journal of Cheminformatics*, **2015**, 7, S2	8.6	98

50	Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease. *Clinical Epigenetics*, **2015**, 7, 108	7.7	39
49	Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease. *Neuropathology and Applied Neurobiology*, **2015**, 41, 471-82	5.2	65
48	Discovery and safety profiling of a potent preclinical candidate, (4-[4-[[(3R)-3-(hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-N-methylbenzamide) (CM-352), for the prevention and treatment of hemorrhage. *Journal of Medicinal Chemistry*, **2015**, 58, 2941-57	8.3	10
47	Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead. *Journal of Medicinal Chemistry* , **2015**, 58, 2465-88	8.3	17
46	Phosphodiesterase inhibition in cognitive decline. *Journal of Alzheimers Disease*, **2014**, 42 Suppl 4, S561-73	4.3	21
45	Discovery of selective ligands for telomeric RNA G-quadruplexes (TERRA) through 19F-NMR based fragment screening. *ACS Chemical Biology*, **2014**, 9, 1559-66	4.9	50
44	Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. *Neurobiology of Aging*, **2014**, 35, 2603-2616	5.6	55
43	P230Metalloproteinases inhibition: a new approach to reduce hemorrhage and blood transfusions. *Cardiovascular Research*, **2014**, 103, S41.2-S41	9.9	
42	Inhibition of the Methyltransferase G9a with Small Molecules As a New Therapeutic Strategy for Treatment of Hematological Malignancies. *Blood*, **2014**, 124, 3532-3532	2.2	1
41	Epigenetic drugs in Alzheimer's disease. *Biomolecular Concepts*, **2013**, 4, 433-45	3.7	26
40	Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. *Neuropharmacology*, **2013**, 64, 114-23	5.5	109
39	Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 1591-7	2.9	36
38	Imidazo[1,2-a]pyrazines as novel PI3K inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 1874-8	2.9	23
37	Identification of ETP-46321, a potent and orally bioavailable PI3K □□nhibitor. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 3460-6	2.9	21
36	Conformational selection versus induced fit in kinases: the case of PI3K-□*Angewandte Chemie - International Edition*, **2012**, 51, 642-6	16.4	15
35	Using novel descriptor accounting for ligand-receptor interactions to define and visually explore biologically relevant chemical space. *Journal of Chemical Information and Modeling*, **2012**, 52, 1086-102	6.1	9
34	Phosphodiesterases as therapeutic targets for Alzheimer's disease. *ACS Chemical Neuroscience*, **2012**, 3, 832-44	5.7	180
33	Biologically relevant chemical space navigator: from patent and structure-activity relationship analysis to library acquisition and design. *Journal of Chemical Information and Modeling*, **2012**, 52, 3123-37	6.1	18

32	Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 5208-14	2.9	17
31	Conformational Selection versus Induced Fit in Kinases: The Case of PI3K-□*Angewandte Chemie*, **2012**, 124, 666-670	3.6	3
30	Fragment-hopping-based discovery of a novel chemical series of proto-oncogene PIM-1 kinase inhibitors. *PLoS ONE*, **2012**, 7, e45964	3.7	13
29	Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. *Cancer Letters*, **2011**, 300, 145-53	9.9	50
28	Computational medicinal chemistry in fragment-based drug discovery: what, how and when. *Future Medicinal Chemistry*, **2011**, 3, 95-134	4.1	16
27	Centralizing discovery information: from logistics to knowledge at a public organization. *Combinatorial Chemistry and High Throughput Screening*, **2011**, 14, 429-49	1.3	3
26	Defining the mechanism of action of 4-phenylbutyrate to develop a small-molecule-based therapy for Alzheimer's disease. *Current Medicinal Chemistry*, **2011**, 18, 5545-53	4.3	20
25	A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. *Nature Structural and Molecular Biology*, **2011**, 18, 721-7	17.6	358
24	Discovery of 1,5-disubstituted pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor. *ACS Chemical Neuroscience*, **2010**, 1, 788-95	5.7	19
23	Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach. *Journal of Medicinal Chemistry*, **2010**, 53, 6618-28	8.3	30
22	An integrated one-step system to extract, analyze and annotate all relevant information from image-based cell screening of chemical libraries. *Molecular BioSystems*, **2010**, 6, 711-20		8
21	Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. *Journal of Biological Chemistry*, **2009**, 284, 28392-28400	5.4	63
20	In vivo, in vitro and in silico methods for small molecule transfer across the BBB. *Journal of Pharmaceutical Sciences*, **2009**, 98, 4429-68	3.9	109
19	Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. *Oncogene*, **2009**, 28, 781-91	9.1	221
18	Novel approach for chemotype hopping based on annotated databases of chemically feasible fragments and a prospective case study: new melanin concentrating hormone antagonists. *Journal of Medicinal Chemistry*, **2009**, 52, 2076-89	8.3	26
17	Optimizing the performance of in silico ADMET general models according to local requirements: MARS approach. solubility estimations as case study. *Journal of Chemical Information and Modeling*, **2009**, 49, 2837-50	6.1	9
16	Synthesis of fluoroalkylated beta-aminophosphonates and pyridines from primary beta-enaminophosphonates. *Journal of Organic Chemistry*, **2008**, 73, 4568-74	4.2	39
15	Assessment of additive/nonadditive effects in structure-activity relationships: implications for iterative drug design. *Journal of Medicinal Chemistry*, **2008**, 51, 7552-62	8.3	48

14	ICAM-1 peptide inhibitors of T-cell adhesion bind to the allosteric site of LFA-1. An NMR characterization. *Chemical Biology and Drug Design*, **2007**, 70, 347-53	2.9	19
13	Mechanism and structure-activity relationships of norspermidine-based peptidic inhibitors of trypanothione reductase. *Bioorganic and Medicinal Chemistry*, **2005**, 13, 4513-26	3.4	20
12	Synthesis of novel 2,5-dihydro-1,5,2-diazaphosphinines from primary enamine phosphonates and from alkyl phosphonates. *Tetrahedron*, **2005**, 61, 1087-1094	2.4	12
11	Preparation of fluoroalkyl imines, amines, enamines, ketones, alpha-amino carbonyls, and alpha-amino acids from primary enamine phosphonates. *Journal of Organic Chemistry*, **2004**, 69, 8767-74	4.2	49
10	Fluoroalkyl alpha,beta-unsaturated imines. Valuable synthetic intermediates from primary fluorinated enamine phosphonates. *Organic Letters*, **2002**, 4, 769-72	6.2	39
9	The AhpC and AhpD antioxidant defense system of Mycobacterium tuberculosis. *Journal of Biological Chemistry*, **2000**, 275, 18801-9	5.4	104
8	A new and efficient strategy for the preparation of 1,5,2-diazaphosphorines from primary β-enaminophosphonates. *Tetrahedron*, **1999**, 55, 3091-3104	2.4	17
7	An easy strategy for the synthesis of 5-phosphorylated pyrimidin-2,4-diones from β-phosphine oxide and phosphonate enamines. *Tetrahedron*, **1999**, 55, 3105-3116	2.4	18
6	A simple synthesis of 3-phosphonyl-4-aminoquinolines from β-enaminophosphonates. *Tetrahedron*, **1999**, 55, 5947-5964	2.4	54
5	A simple and efficient strategy for the preparation of 5-phosphorylated imidazol-2-ones from primary β-enaminophosphonates. *Tetrahedron*, **1998**, 54, 2281-2288	2.4	23
4	An Efficient Synthesis of 3-Phosphorylated 4(1H)-Pyridones and 4-Chloropyridines fromb-Enaminophosphonates. *Heterocycles*, **1998**, 47, 517	0.8	10
3	A one pot synthesis of polysubstituted pyridines from metallated alkylphosphonates, nitriles and α,β-unsaturated ketones. *Tetrahedron Letters*, **1996**, 37, 4577-4580	2	45
2	Synthesis of 5-Phosphonyl-2(1H)-pyridones from Primary b-Enaminophosphonate and Acetylenic Esters. *Heterocycles*, **1995**, 41, 1915	0.8	24
1	Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease		1